AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
Since August 2002, the two companies have been collaborating in the development of intraarticular injection for treating rheumatism and osteoarthritis.
After evaluating the validity of their joint development efforts, Seikagaku has decided to withdraw from the development project. In the meantime, AnGes MG plans to continue the development of an NFkB decoy-oligo-based intraarticula injection.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Feb 7, 2006|
|Previous Article:||Fuji Heavy Industries to License Lithium Ion Capacity Technology to Nihon Micro Coating.|
|Next Article:||Nippon Milk Community to Bring to Market New Probiotic Yogurt Series.|